Screener
Corcept Therapeutics CORT Return on equity
Return on equity at other companies
Other financials
Where this comes from
Calculated from Corcept Therapeutics’s reported figures.
Based on trailing twelve months.
The source filing: Corcept Therapeutics’s 10-Q, filed July 29, 2026. Open the filing →
- Filed
- Jul 29, 2026, 4:09 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001628280-26-050613
FAQ
- What is Corcept Therapeutics's return on equity?
- Corcept Therapeutics (CORT) reported return on equity of 8.2% in Q2 2026.
- How has Corcept Therapeutics's return on equity changed year-over-year?
- Corcept Therapeutics's return on equity decreased by 62.1% year-over-year, from 21.7% to 8.2%.
- What is the long-term trend for Corcept Therapeutics's return on equity?
- Over 5 years (2020 to 2025), Corcept Therapeutics's return on equity has grown at a -8.7% compound annual growth rate (CAGR), from 23.7% to 15%.
- What does return on equity mean?
- Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.
Ask your AI about Corcept Therapeutics's return on equity.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude